The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the AVDL is 0.50%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. The Institutional ownership for the AVDL is 52.30%.
Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that AVDL. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public. The insider transactions of the company (6-month change in insider ownerships) for the Avadel Pharmaceuticals plc (NASDAQ:AVDL) is 0.00%.
Institutional transactions is the amount of a Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the AVDL is -1.49%.
A Healthcare sector firm, Avadel Pharmaceuticals plc (NASDAQ:AVDL) stock ticked up 1.81% on Monday and when day-trade ended the stock finally concluded at $3.37 and number of shares that changed hands during the day are 269172. The number of shares AVDL stock currently held by all its shareholders are 36.80 and floated shares, the number of shares are available for trading in an open market on last trading day are 35.64. The average volume of shares for 3 months is 220.17 and AVDL stock value has moved between $1.03 – 4.81 in last one year.
The Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s latest earnings date is 8/9/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The valuable gross margin for Avadel Pharmaceuticals plc (NASDAQ:AVDL) is 80.90% and the stock has gained 30.62% in 2019 to date.
Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s monthly stock performance is 61.24%, the quarterly performance is 21.66%, the half year performance is calculated as 127.70%. The yearly performance of AVDL is -23.41%.
The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Avadel Pharmaceuticals plc (NASDAQ:AVDL) weekly volatility is measured as 12.75% and monthly volatility measured as 11.00%.
Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. AVDL return on assets is -50.70%, the return on equity (ROE) of the Avadel Pharmaceuticals plc (NASDAQ:AVDL) is -983.90%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions, and AVDL return on investment is -63.30%.
Analysts mean target price for Avadel Pharmaceuticals plc (NASDAQ:AVDL) is $4.50 while analysts mean recommendation is 1.50. The current share price indicates that stock is -30.23% away from its one year high and is moving 227.18% ahead of its 52-week low. AVDL’s distance from 20 day simple moving average is 36.52% and distance from 50-Day simple moving average is 46.59%.
